

SPECIAL AND EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING

"AgomAb Therapeutics"

Limited liability company
at 2600 Antwerp (Berchem), Posthoflei 1, box 6
CBE 0674.527.310 – RLE Antwerp (section Antwerp)

APPOINTMENT OF DIRECTORS

CONSOLIDATION AND SPLIT OF SUBSCRIPTION RIGHTS

Today, 11 September 2026.

At 2600 Antwerp (Berchem), Posthoflei 1, box 6.

Before me, Mr Eric DE BIE, a notary public with office in Antwerp (Ekeren), who carries out his duties within the notary firm "De Bie Notarissen", with its registered office in Antwerp (Ekeren), Driehoekstraat 182C, replacing his colleague Mr Tim CARNEWAL, a notary public with office in Brussels (first canton), who carries out his duties within the notary firm "Berquin Notarissen", with its registered office in Brussels, Lloyd Georgelaan 11, who is legally prevented due to his location,

IS BEING HELD

The special and extraordinary general shareholders' meeting of the limited liability company "**AgomAb Therapeutics**", with its registered office at 2600 Antwerp (Berchem), Posthoflei 1, box 6, hereinafter referred to as the "Company".

IDENTIFICATION OF THE COMPANY

The Company was incorporated by deed executed before Mr Peter Van Melkebeke, a notary public in Brussels, on 13 April 2017, an extract of which was published in the Annexes to the Belgian Official Gazette of 18 April of that year, under number 17309448.

The Company's Articles of Association have been amended on several occasions, most recently by deed executed before Mr Tim Carnewal, a notary in Brussels, on 12 March 2026, an extract of which was published in the the Annexes to the Belgian Official Gazette of 17 April of that year, under number 26325057.

The Company is registered in the Register of Legal Entities in Antwerp (section Antwerp) under number 0674.527.310.

START OF THE MEETINGS - COMPOSITION OF THE BUREAU

The meeting is opened at 2:30 pm with Ms Ellen LEFEVER, residing at Heidelaan 15, 2547 Lint, acting as chair, who appoints Mr Mats MUYS, residing at Bistkapellei 5, 2180 Antwerp (Ekeren), as secretary.

In view of the limited number of attendees, no tellers are appointed.

AGENDA AND PROPOSED RESOLUTIONS

The chair explains that the agenda (including the proposed resolutions) for the current

special general shareholders' meeting (hereinafter also referred to as the "**SGM**") and the extraordinary general shareholders' meeting (hereinafter also referred to as the "**EGM**") are as follows:

A. SPECIAL GENERAL SHAREHOLDERS' MEETING

1. Appointment of Mr. Marino Garcia as a member of the Board of Directors. ⁽¹⁾

Proposed resolution: As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the SGM resolves to appoint Mr. Marino Garcia, who elects domicile at the Company's registered office, as a non-executive director for a term of four years ending immediately after the annual general meeting to be held in 2030. For the performance and duration of his mandate, Mr. Garcia is entitled to the annual remuneration as approved by the extraordinary general meeting of shareholders of the Company on 15 January 2026 and as determined in the notarial deed of 9 February 2026.

2. Appointment of Dr. Naimish Patel as a member of the Board of Directors. ⁽²⁾

Proposed resolution: As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the SGM resolves to appoint Dr. Naimish Patel, who elects domicile at the Company's registered office, as a non-executive director for a term of four years ending immediately after the annual general meeting to be held in 2030. For the performance and duration of his mandate, Dr. Patel is entitled to the annual remuneration as approved by the extraordinary general meeting of shareholders of the Company on 15 January 2026 and as determined in the notarial deed of 9 February 2026.

⁽¹⁾ For further information regarding Mr. Garcia, please refer to his biography available on the Company's website.

⁽²⁾ For further information regarding Dr. Patel, please refer to his biography available on the Company's website.

B. EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING

1. Consolidation and split of the Pre-IPO Subscription Rights

Explanatory note: Within the framework of the initial public offering by the Company of new shares represented by American Depositary Shares (the "**IPO**"), all of the ordinary shares of the Company that were outstanding immediately prior to the completion of the IPO (the "**IPO Closing**") were split into a new and increased number of shares pursuant to a ratio (the "**Split Ratio**") of 21.6450216450216 new ordinary shares for one (1) existing ordinary share (the "**IPO Stock Split**"). The IPO Stock Split was approved in principle by the extraordinary general shareholders' meeting held on 15 January 2026 (the "**IPO EGM**"), was further implemented on the basis of powers of attorney granted by the IPO EGM and entered into force on 9 February 2026 at the time of the IPO Closing. The IPO EGM also decided that the IPO Stock Split was, mutatis mutandis, to be effected in the same manner and in accordance with the same rules and ratios with respect to the outstanding subscription rights of the Company at the time of the

implementation of the IPO Stock Split (such subscription rights, the "**Pre-IPO Subscription Rights**"), in each case in the manner contemplated in the respective terms and conditions of these subscription rights. As a result of the IPO Stock Split, therefore, each Pre-IPO Subscription Right currently entitles the holder thereof to subscribe for 21.6450216450216 new ordinary shares per Pre-IPO Subscription Right (subject to the applicable terms and conditions of such subscription right). The subscription rights that were created immediately following the IPO Closing (the "**Post-IPO Subscription Rights**") each entitle the holder thereof to subscribe for one (1) new ordinary share per Post-IPO Subscription Right (subject to the applicable terms and conditions of such subscription right). In order to simplify the management of the Pre-IPO Subscription Rights, the Board of Directors proposes to the EGM to consolidate and split the respective Pre-IPO Subscription Rights into a greater number of subscription rights in accordance with the Split Ratio, such that each Pre-IPO Subscription Right entitles the holder thereof to subscribe for one (1) new ordinary share, and to adjust the exercise price of the respective Pre-IPO Subscription Rights proportionally in accordance with the same Split Ratio. All other features, terms and conditions of the Pre-IPO Subscription Rights remain unchanged. As the intrinsic value of the Pre-IPO Subscription Rights immediately before and immediately after the Subscription Right Split (as defined below) is maintained, the proposed consolidation and split should be neutral from a financial and economic perspective.

Proposed resolution: The EGM has taken note of the aforementioned explanatory note and resolves, with effect as from the date of the EGM, to consolidate the Pre-IPO Subscription Rights and to split the Pre-IPO Subscription Rights into a greater number of subscription rights in accordance with the Split Ratio (the "**Subscription Right Split**"), subject to the following terms and conditions:

- (a) All of the Pre-IPO Subscription Rights that are outstanding on the date of the EGM shall, by operation of law and without any further act or formality, be consolidated and split into a greater number of subscription rights at a ratio equal to the Split Ratio, so that each Pre-IPO Subscription Right shall be split into 21.6450216450216 new subscription rights. As a result of and in connection with such consolidation and split: (i) each subscription right following the Subscription Right Split shall entitle the holder thereof to subscribe for one (1) new ordinary share of the Company (subject to the applicable terms and conditions of such subscription right, as amended pursuant to the present EGM resolution); and (ii) the exercise price of each subscription right following the Subscription Right Split shall be equal to the applicable exercise price of the relevant Pre-IPO Subscription Right prior to the Subscription Right Split divided by the Split Ratio (subject to the rounding provisions set out in paragraph (c) below).
- (b) No fractions of new subscription rights shall be created as a result of the Subscription Right Split. The Subscription Right Split shall be calculated for each holder of Pre-IPO Subscription Rights individually, and this per individual offer of Pre-IPO Subscription Rights issued by the Company within the framework of the same subscription right plan and having the same exercise price. If such calculation

for the Pre-IPO Subscription Rights within such individual offer results in a number of subscription rights that is not a whole number, such number shall be rounded up to the nearest whole number.

- (c) Any calculation of the applicable exercise price of a subscription right following the Subscription Right Split in accordance with paragraph (a) that results in an amount with more than two (2) decimal places shall be rounded to the nearest two (2) decimal places. If the third decimal digit is five (5) or greater, the amount shall be rounded up; otherwise, it shall be rounded down.
- (d) Save for the adjustments to the number of subscription rights and the relevant exercise price resulting from the Subscription Right Split, all other terms and conditions of the Pre-IPO Subscription Rights (such as, the vesting, the term and exercise conditions) shall remain mutatis mutandis unaffected and in full force and effect, except for such amendments as are technically necessary to give effect to the Subscription Right Split. Furthermore, the Subscription Right Split shall not affect the aggregate exercise price payable by a holder upon exercise of all of such holder's subscription rights offered within a given individual offer issued by the Company within the framework of the same subscription right plan and having the same exercise price, except to the extent of any rounding adjustments pursuant to paragraphs (b) and (c).
- (e) The Subscription Right Split shall not apply to the Post-IPO Subscription Rights.
- (f) The Board of Directors is authorised to further implement, administer and execute the Subscription Right Split as provided for in paragraphs (a) to (e) above, including, without limitation, the power to: (i) calculate and record in the subscription right register, relevant subscription right plans and any other records of the Company the new number of subscription rights for each relevant holder of Pre-IPO Subscription Rights, together with the relevant exercise price of such subscription rights; (ii) make such other amendments to the terms and conditions of the subscription rights as may be useful, appropriate or necessary to give effect to the terms and underlying principles of the Subscription Right Split; and (iii) take such other actions and execute such other documents as may be useful, appropriate or necessary in connection with the foregoing. The Board of Directors shall be authorised to (fully or partially) sub-delegate the execution of its powers.

Practical example: The following example illustrates the application of the Subscription Right Split (including the rounding mechanisms set out in paragraphs (b) and (c) above) to hypothetical holders of Pre-IPO Subscription Rights. The example is provided for illustrative purposes only and does not form part of the resolution. Assume that a holder holds 7 Pre-IPO Subscription Rights with an exercise price of EUR 52.13 per subscription right. Following the Subscription Right Split: (i) the number of subscription rights is calculated as $7 \times 21.6450216450216 = 151.5151515151512$, which is rounded up to 152 subscription rights (pursuant to paragraph (b)); and (ii) the exercise price per subscription right is calculated as EUR

$52.13 / 21.6450216450216 = \text{EUR } 2.408406$, which is rounded to EUR 2.41 (pursuant to paragraph (c), the third decimal digit being 8, i.e. equal to or greater than 5). The aggregate exercise price before the Subscription Right Split is EUR 364.91 ($7 \times \text{EUR } 52.13$). The aggregate exercise price after the Subscription Right Split is EUR 366.32 ($152 \times \text{EUR } 2.41$). The difference of EUR 1.41 is de minimis.

VERIFICATIONS DONE BY THE BUREAU – ATTENDANCES

The chair subsequently reports to the meeting on the findings and verifications carried out by the bureau, both during and after the participants' registration formalities, with a view to determining the composition of the special and extraordinary meeting:

1. Convening of the holders of securities

All holders of securities issued by the Company, the statutory auditor, Ohad Hammer, director, and Angelika Jahreis, director, were convened by emails dated 10 August 2026. The other directors of the Company waived the convening formalities for the special and extraordinary meeting during the meeting of the Board of Directors of the Company held on 4 August 2026.

The notice convening the special and extraordinary meeting, together with the accompanying documents, was also made available as of 10 August 2026 on the Company's website (<https://ir.agomab.com/governance/shareholder-meetings>).

Proof of the relevant emails and letters was submitted to the bureau.

As all ordinary shares and subscription rights of the Company have been issued in registered form, the chair notes that the meeting was convened in accordance with Article 7:127 of the Belgian Code of Companies and Associations of 23 March 2019 (as amended from time to time).

Holders of the Company's American Depositary Shares ("ADSS") received the necessary information, documents, and instructions relating to the special and extraordinary meeting from The Bank of New York Mellon, acting in its capacity as depositary, or from the broker, bank, or other nominee through which the holder maintains its ADSS.

2. Attendance to the meeting

In connection to the convening of the special and extraordinary general meeting, the Company's board of directors has determined, in accordance with Article 22 of the Articles of Association, that the right to attend the general meetings and to exercise voting rights (where applicable) would be determined on the basis of the registration of the relevant securities in the relevant register for those securities at 00:00 (CEST) on Friday 4 September 2026 (the "**Record Date**"), irrespective of the number of shares held by the shareholder on the day of the general meetings. Only persons who are holders of shares or subscription rights in the Company on the Record Date are entitled to attend the general meetings and to exercise voting rights (where applicable). This was also set out in the notice convening the special and extraordinary general meetings.

The convening notice also contained additional formalities regarding notification of attendance to the meeting (in accordance with Article 22 of the Articles of Association), the submission of proxies (in accordance with Article 23 of the Articles of Association), and voting by voting form (in accordance with Article 27 of the Articles of Association).

3. Verification of the powers of the participants to the meeting

With regard to attendance to this special and extraordinary general meeting, the bureau verified that Articles 22, 23, 24 and 27 of the Articles of Association has been complied with, which was confirmed by the bureau; the various supporting documents, as well as the original

proxies and voting forms, will be retained in the Company's archives.

The bureau has thus verified that the shares entitled to vote at this special and extraordinary general meeting were correctly registered on the Record Date of 4 September 2026, at 00:00 (Belgian time), and that the shareholders have confirmed their intention to cast their votes by 9 September 2026 at 23:59 (Belgian time) at the latest (the "**Notification Date**").

4. Attendance list

The special and extraordinary meeting is composed of the shareholders who are present, represented or have cast their votes by voting form, and whose surnames, first names or name and legal form, as well as the number of securities that each of them declares to own for the purposes of this meeting, are listed in the attached attendance list.

Consequently, attendance has been recorded by the undersigned notary public in the aforementioned attendance list, to which the parties declare they refer; this attendance list, signed by the members of the bureau who have certified it as accurate, was marked as attachment and signed by me, the notary public.

All powers of attorney and voting forms were received no later than the applicable Notification Date, being 9 September 2026 at 23:59 (CEST), and are recognised as valid by the bureau.

5. Verification of the quorum

The special general meeting may validly deliberate and resolve on the proposed resolutions on the agenda of the special general meeting, irrespective of the number of shares present or represented at the meeting, in accordance with Article 28.2 of the Articles of Association.

In order to deliberate and resolve on the proposed resolutions on the agenda of the extraordinary general meeting, the shareholders present or represented at this extraordinary general meeting must represent at least half of the Company's share capital, in accordance with Article 7:153 of the Companies and Associations Code.

The chair has established that the attendance list shows that 33,638,719 shares out of a total of 49,247,975 are represented, of which shareholders representing 10,335,025 shares have voted by voting form.

Consequently, the special and extraordinary general meeting is validly constituted and may deliberate and resolve on all proposals for resolutions on the agenda of the special and extraordinary general meeting.

VOTING MODALITIES

The chair reminds the meeting that only shareholders who are present or who have cast their votes by voting form, and shareholders represented by proxy, are entitled to take part in the vote.

The chair further reminds the meeting that, for the proposed resolutions on the agenda of the special general meeting to be validly adopted, they must be passed by a simple majority of votes, in accordance with Article 28.3 of the Articles of Association.

The chair also reminds the meeting that, for the resolution on the agenda of the extraordinary general meeting to be validly adopted, it must be passed by three-quarters of the votes cast, in accordance with Article 7:153 of the Companies and Associations Code.

QUESTIONS

In accordance with Article 7:139 of the Companies and Associations Code, the chair invites participants to ask questions relating to the items on the agenda.

The chair announced that no shareholder had made use of the opportunity to submit questions in writing in advance regarding the special and extraordinary general meeting, as provided for in Article 7:139 of the Companies and Associations Code.

No questions were asked at the meeting.

DELIBERATIONS - RESOLUTIONS

The meeting then proceeded to the agenda. The chair discussed the explanatory notes and the practical example included in the meeting's agenda. Following deliberation, the meeting took the following decisions. Those present attended both the special and the extraordinary meeting.

A. SPECIAL GENERAL SHAREHOLDERS' MEETING

FIRST RESOLUTION: Appointment of Mr. Marino Garcia as member of the board of directors.

As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the SGM resolves to appoint Mr. Marino Garcia, who elects domicile at the Company's registered office, as a non-executive director for a term of four years ending immediately after the annual general meeting to be held in 2030. For the performance and duration of his mandate, Mr. Garcia is entitled to the annual remuneration as approved by the extraordinary general meeting of shareholders of the Company on 15 January 2026 and as determined in the notarial deed of 9 February 2026.

Vote:

The proposal is put to the vote. It is adopted as set out below:

1/ Number of shares in respect of which valid votes have been cast: 33,638,719

2/ Percentage of the share capital represented by the above number of shares:
76.7217%

3/ Number of valid votes cast
of which

FOR	33,637,910
AGAINST	505
ABSTAIN	304

SECOND RESOLUTION: Appointment of Dr. Naimish Patel as member of the board of directors.

As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the SGM resolves to appoint Dr. Naimish Patel, who elects domicile at the Company's registered office, as a non-executive director for a term of four years ending immediately after the annual general meeting to be held in 2030. For the performance and duration of his mandate, Dr. Patel is entitled to the annual remuneration as approved by the extraordinary general meeting of shareholders of the Company on 15 January 2026 and as determined in the notarial deed of February 9, 2026.

Vote:

The proposal is put to the vote. It is adopted as set out below:

1/ Number of shares in respect of which valid votes have been cast: 33,638,719

2/ Percentage of the share capital represented by the above number of shares:
76,7217%

3/ Number of valid votes cast
of which

FOR	33,637,912
AGAINST	505
ABSTAIN	302

B. EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING

FIRST RESOLUTION: Consolidation and split of the Pre-IPO Subscription Rights.

The EGM has taken note of the aforementioned explanatory note and resolves, with effect as from the date of the EGM, to consolidate the Pre-IPO Subscription Rights and to split the Pre-IPO Subscription Rights into a greater number of subscription rights in accordance with the Split Ratio (the "**Subscription Right Split**"), subject to the following terms and conditions:

- (a) All of the Pre-IPO Subscription Rights that are outstanding on the date of the EGM shall, by operation of law and without any further act or formality, be consolidated and split into a greater number of subscription rights at a ratio equal to the Split Ratio, so that each Pre-IPO Subscription Right shall be split into 21.6450216450216 new subscription rights. As a result of and in connection with such consolidation and split: (i) each subscription right following the Subscription Right Split shall entitle the holder thereof to subscribe for one (1) new ordinary share of the Company (subject to the applicable terms and conditions of such subscription right, as amended pursuant to the present EGM resolution); and (ii) the exercise price of each subscription right following the Subscription Right Split shall be equal to the applicable exercise price of the relevant Pre-IPO Subscription Right prior to the Subscription Right Split divided by the Split Ratio (subject to the rounding provisions set out in paragraph (c) below).
- (b) No fractions of new subscription rights shall be created as a result of the Subscription Right Split. The Subscription Right Split shall be calculated for each holder of Pre-IPO Subscription Rights individually, and this per individual offer of Pre-IPO Subscription Rights issued by the Company within the framework of the same subscription right plan and having the same exercise price. If such calculation for the Pre-IPO Subscription Rights within such individual offer results in a number of subscription rights that is not a whole number, such number shall be rounded up to the nearest whole number.
- (c) Any calculation of the applicable exercise price of a subscription right following the Subscription Right Split in accordance with paragraph (a) that results in an amount with more than two (2) decimal places shall be rounded to the nearest two (2) decimal places. If the third decimal digit is five (5) or greater, the amount shall be rounded up; otherwise, it shall be rounded down.
- (d) Save for the adjustments to the number of subscription rights and the relevant exercise price resulting from the Subscription Right Split, all other terms and conditions of the Pre-IPO Subscription Rights (such as, the vesting, the term and exercise conditions) shall remain mutatis mutandis unaffected and in full force and effect, except for such amendments as are technically necessary to give effect to the Subscription Right Split. Furthermore, the Subscription Right Split shall not affect the aggregate exercise price payable by a holder upon exercise of all of such holder's subscription rights offered within a given individual offer issued by the Company within the framework of the same subscription right plan and having the

same exercise price, except to the extent of any rounding adjustments pursuant to paragraphs (b) and (c).

- (e) The Subscription Right Split shall not apply to the Post-IPO Subscription Rights.
- (f) The Board of Directors is authorised to further implement, administer and execute the Subscription Right Split as provided for in paragraphs (a) to (e) above, including, without limitation, the power to: (i) calculate and record in the subscription right register, relevant subscription right plans and any other records of the Company the new number of subscription rights for each relevant holder of Pre-IPO Subscription Rights, together with the relevant exercise price of such subscription rights; (ii) make such other amendments to the terms and conditions of the subscription rights as may be useful, appropriate or necessary to give effect to the terms and underlying principles of the Subscription Right Split; and (iii) take such other actions and execute such other documents as may be useful, appropriate or necessary in connection with the foregoing. The Board of Directors shall be authorised to (fully or partially) sub-delegate the execution of its powers.

Practical example: The following example illustrates the application of the Subscription Right Split (including the rounding mechanisms set out in paragraphs (b) and (c) above) to hypothetical holders of Pre-IPO Subscription Rights. The example is provided for illustrative purposes only and does not form part of the resolution. Assume that a holder holds 7 Pre-IPO Subscription Rights with an exercise price of EUR 52.13 per subscription right. Following the Subscription Right Split: (i) the number of subscription rights is calculated as $7 \times 21.6450216450216 = 151.51515151512$, which is rounded up to 152 subscription rights (pursuant to paragraph (b)); and (ii) the exercise price per subscription right is calculated as $\text{EUR } 52.13 / 21.6450216450216 = \text{EUR } 2.408406$, which is rounded to EUR 2.41 (pursuant to paragraph (c), the third decimal digit being 8, i.e. equal to or greater than 5). The aggregate exercise price before the Subscription Right Split is EUR 364.91 ($7 \times \text{EUR } 52.13$). The aggregate exercise price after the Subscription Right Split is EUR 366.32 ($152 \times \text{EUR } 2.41$). The difference of EUR 1.41 is de minimis.

Vote:

The proposal is put to the vote. It is adopted as set out below:

1/ Number of shares in respect of which valid votes have been cast: 33,638,719

2/ Percentage of the share capital represented by the above number of shares: 76,7217%

3/ Number of valid votes cast
of which

FOR	33,638,147
AGAINST	506
ABSTAIN	66

NOTARIAL FINAL PROVISIONS

INFORMATION - ADVICE

The shareholders, represented as stated where applicable, declare that the notary public has fully informed them of the rights, obligations and liabilities arising from the legal acts in which they are involved and that he has provided them with impartial advice.

DOCUMENT DUTY (Code of Miscellaneous Duties and Taxes)

A duty of one hundred euros (100.00 EUR), paid on declaration by the undersigned notary.

COPY OF DEED (NABAN)

An official copy of this deed will be available in the Notarial Deeds Database (NABAN). This database can only be accessed using an e-ID card or via the 'itsme' app.

READING OF THE MINUTES

The minutes were read out in full in respect of the entries contained in Article 12, paragraphs 1 and 2, of the Notarial Organisation Act, and the amendments made to the draft minutes that had been circulated in advance.

The notary public explained the minutes.

IDENTITY

The notary certifies the identity details of the chair, the members of the bureau and the shareholders – or, where applicable, their representatives – who have asked the undersigned notary to sign these minutes, upon presentation of their identity cards.

CLOSING OF THE MEETINGS

The special and extraordinary meetings are adjourned at 2:50 pm.

MINUTES

Drawn up at the place and on the date stated above.

Following a partial reading and explanation, the chair, the members of the bureau and the shareholders – or, where applicable, their representatives – who so requested, signed this document together with me, the notary public.